Mikael Norman

Mikael Norman

Auto-generated profile, based on publicly available information

Mikael Norman

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CACharlotte Admyre
Charlotte Admyre
SJSara M. Johansson
Sara M. Johansson
KQKhaleda Rahman Qazi
Khaleda Rahman Qazi
JFJan-Jonas Filén
Jan-Jonas Filén
RLRiitta Lahesmaa
Riitta Lahesmaa
SGSusanne Gabrielsson
Susanne Gabrielsson
Breast milk is a complex liquid with immune-competent cells and soluble proteins that provide immunity to the infant and affect the maturation of the infant’s immune system. Exosomes are nanovesicles (30–100 nm) with an endosome-derived limiting membrane secreted by a diverse range of cell types. Because exosomes carry immunorelevant structures, they are suggested to participate in directing the immune response. We hypothesized that human breast milk contain exosomes, which may be important for the development of the infant’s immune system. We isolated vesicles from the human colostrum and mature breast milk by ultracentrifugations and/or immuno-isolation on paramagnetic beads. We found that the vesicles displayed a typical exosome-like size and morphology as analyzed by electron microscopy. Furthermore, they floated at a density between 1.10 and 1.18 g/ml in a sucrose gradient, corresponding to the known density of exosomes. In addition, MHC classes I and II, CD63, CD81, and CD86 were detected on the vesicles by flow cytometry. Western blot and mass spectrometry further confirmed the presence of several exosome-associated molecules. Functional analysis revealed that the vesicle preparation inhibited anti-CD3-induced IL-2 and IFN-γ production from allogeneic and autologous PBMC. In addition, an increased number of Foxp3+CD4+CD25+ T regulatory cells were observed in PBMC incubated with milk vesicle preparations. We conclude that human breast milk contains exosomes with the capacity to influence immune responses.

3 June 2009 in JAMA
Verified
Journal Article
Closed access
PDF file
EGEXPRESS Group
EXPRESS Group
VFVineta Fellman
Vineta Fellman
LHLena Hellström-Westas
Lena Hellström-Westas
MNMikael Norman
Mikael Norman
MWMagnus Westgren
Magnus Westgren
MWMargareta Wennergren
Margareta Wennergren
Research from JAMA — One-Year Survival of Extremely Preterm Infants After Active Perinatal Care in Sweden

1 May 2013 in JAMA
Verified
Journal Article
Open access
PDF file
FSFredrik Serenius
Fredrik Serenius
KKKarin Källén
Karin Källén
MBMats Blennow
Mats Blennow
UEUwe Ewald
Uwe Ewald
VFVineta Fellman
Vineta Fellman
FGfor the EXPRESS Group
for the EXPRESS Group
A proactive approach to resuscitation and intensive care of extremely preterm infants (50%) impairment rates.12

12 August 2009 in Diabetes Care
Verified
Journal Article
Open access
MPMartina Persson
Martina Persson
MNMikael Norman
Mikael Norman
UHUlf Hanson
Ulf Hanson
OBJECTIVE: To perform comparative analyses of obstetric and perinatal outcomes between type 1 diabetic pregnancies and the general obstetric population in Sweden between 1991 and 2003. RESEARCH DESIGN AND METHODS: This was a population-based study. Data were obtained from the Medical Birth Registry, covering >98% of all pregnancies in Sweden. A total of 5,089 type 1 diabetic pregnancies and 1,260,207 control pregnancies were included. Odds ratios (ORs) were adjusted for group differences in maternal age, parity, BMI, chronic hypertensive disease, smoking habits, and ethnicity. RESULTS: In type 1 diabetes, preeclampsia was significantly more frequent (OR 4.47 [3.77–5.31]) as was delivery by cesarean section (5.31 [4.97–5.69]) compared with results for the general population. Stillbirth (3.34 [2.46–4.55]), perinatal mortality (3.29 [2.50–4.33]), and major malformations (2.50 [2.13–2.94]) were more common in type 1 diabetic than in control pregnancies. The risk of very preterm birth (<32 gestational weeks) was also higher among type 1 diabetic women (3.08 [2.45–3.87]). The incidence of fetal macrosomia (birth weight ≥2 SD above the mean) was increased in the diabetic group (11.45 [10.61–12.36]). CONCLUSIONS: Type 1 diabetes in pregnancy is still associated with considerably increased rates of adverse obstetric and perinatal outcomes. The eightfold increased risk for fetal macrosomia in type 1 diabetic pregnancies is unexpected and warrants further investigation.

26 March 2019 in JAMA
Verified
Journal Article
Open access
PDF file
MNMikael Norman
Mikael Norman
BHBoubou Hallberg
Boubou Hallberg
TAThomas Abrahamsson
Thomas Abrahamsson
LBLars J. Björklund
Lars J. Björklund
MDMagnus Domellöf
Magnus Domellöf
SHStellan Håkansson
Stellan Håkansson
Importance: Since 2004-2007, national guidelines and recommendations have been developed for the management of extremely preterm births in Sweden. If and how more uniform management has affected infant survival is unknown.Objective: To compare survival of extremely preterm infants born during 2004-2007 with survival of infants born during 2014-2016.Design, Setting and Participants: All births at 22-26 weeks’ gestational age (n = 2205) between April 1, 2004, and March 31, 2007, and between January 1, 2014, and December 31, 2016, in Sweden were studied. Prospective data collection was used during 2004-2007. Data were obtained from the Swedish pregnancy, medical birth, and neonatal quality registries during 2014-2016.Exposures: Delivery at 22-26 weeks’ gestational age.Main Outcomes and Measures: The primary outcome was infant survival to the age of 1 year. The secondary outcome was 1-year survival among live-born infants who did not have any major neonatal morbidity (specifically, without intraventricular hemorrhage grade 3-4, cystic periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity stage 3-5, or severe bronchopulmonary dysplasia).Results: During 2004-2007, 1009 births (3.3/1000 of all births) occurred at 22-26 weeks’ gestational age compared with 1196 births (3.4/1000 of all births) during 2014-2016 (P = .61). One-year survival among live-born infants at 22-26 weeks’ gestational age was significantly lower during 2004-2007 (497 of 705 infants [70%]) than during 2014-2016 (711 of 923 infants [77%]) (difference, −7% [95% CI, −11% to −2.2%], P = .003). One-year survival among live-born infants at 22-26 weeks’ gestational age and without any major neonatal morbidity was significantly lower during 2004-2007 (226 of 705 infants [32%]) than during 2014-2016 (355 of 923 infants [38%]) (difference, −6% [95% CI, −11% to −1.7%], P = .008).Conclusions and Relevance: Among live births at 22-26 weeks’ gestational age in Sweden, 1-year survival improved between 2004-2007 and 2014-2016.

1 April 2013 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
CCClara Cho
Clara Cho
MNMikael Norman
Mikael Norman